Goldman Sachs
XBIT icon

Goldman Sachs’s XBiotech XBIT Stock Holding History

Goldman Sachs’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-35,000
Closed -$165K – 6888
2017
Q2 		$165K Buy
+35,000
New +$335K ﹤0.01% 5906

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's XBIT Position: Q1 2026 in Review

Goldman Sachs sold out of XBiotech (XBIT) in Q1 2026, closing a stake of 16,831 shares — an estimated $40.2K sold.

Goldman Sachs first reported a position in XBIT in Q3 2015 and held it in 34 quarters. The position peaked at $1.63M in Q1 2017. 37 funds tracked by Wall St. Rank hold XBIT as of Q1 2026.

  • Goldman Sachs reported no remaining XBiotech position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 16,831 XBiotech shares in Q1 2026, an estimated $40.2K.
  • Goldman Sachs first reported a position in XBiotech in Q3 2015 and held it in 34 quarters.
  • Goldman Sachs's XBiotech position peaked at $1.63M in Q1 2017.
  • 37 funds tracked by Wall St. Rank held XBiotech as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.